Limits...
Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.

Saxenian H, Hecht R, Kaddar M, Schmitt S, Ryckman T, Cornejo S - Health Policy Plan (2014)

Bottom Line: Although all possess certain strengths, each country displayed weaknesses in some of the following areas: budgeting for vaccine purchase, national procurement practices, performance of national regulatory agencies, and technical capacity for vaccine planning and advocacy.The 2012 pilot experience further demonstrated the value of transition planning processes and tools.As a result, GAVI has decided to continue with transition planning in 2013 and beyond.

View Article: PubMed Central - PubMed

Affiliation: Consultant to Results for Development Institute, Washington, DC 20005, USA, Results for Development Institute, Washington, DC 20005, USA, World Health Organization, 1211 Geneva, Switzerland, Consultant to World Health Organization, 1211 Geneva, Switzerland, GAVI Alliance, 1202 Geneva, Switzerland rhecht@resultsfordevelopment.org.

No MeSH data available.


Related in: MedlinePlus

Country and GAVI financing for GAVI-supported vaccines for the 14 graduating countries, 2012–18 (US$). Source: GAVI Alliance, estimates as of 26 September 2013. Note: These estimates are based on introduction dates and doses from GAVI’s adjusted demand forecast. For vaccines introduced in 2012, GAVI’s last year of support would be 2015. For introduction in 2013, GAVI’s last year of support is 2016. For introduction in 2014, GAVI’s last year of support is 2017.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325534&req=5

czu003-F1: Country and GAVI financing for GAVI-supported vaccines for the 14 graduating countries, 2012–18 (US$). Source: GAVI Alliance, estimates as of 26 September 2013. Note: These estimates are based on introduction dates and doses from GAVI’s adjusted demand forecast. For vaccines introduced in 2012, GAVI’s last year of support would be 2015. For introduction in 2013, GAVI’s last year of support is 2016. For introduction in 2014, GAVI’s last year of support is 2017.

Mentions: Overall, the 14 countries are expected to face varying challenges in meeting the costs of their new GAVI-supported vaccines, as external support from GAVI is phased out (see Figure 1). Total required funding for new vaccines (and injection supplies) is anticipated to grow from under US$30 million in 2012 to almost US$90 million by 2018. Funding from GAVI will peak in 2014, at US$52 million, and will then decline to zero by 2018. The financial resources required from the 14 graduating country governments will therefore need to increase from about US$8 million in 2012 to US$90 million in 2018. These projections assume that countries will obtain GAVI prices after GAVI support ends, although alternative country-specific price assumptions were used in discussions with countries. In addition, countries will need to continue to finance non-vaccine immunization costs, such as health workers, transport, demand creation and community mobilization activities, and the supply chain for vaccines.Figure 1


Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.

Saxenian H, Hecht R, Kaddar M, Schmitt S, Ryckman T, Cornejo S - Health Policy Plan (2014)

Country and GAVI financing for GAVI-supported vaccines for the 14 graduating countries, 2012–18 (US$). Source: GAVI Alliance, estimates as of 26 September 2013. Note: These estimates are based on introduction dates and doses from GAVI’s adjusted demand forecast. For vaccines introduced in 2012, GAVI’s last year of support would be 2015. For introduction in 2013, GAVI’s last year of support is 2016. For introduction in 2014, GAVI’s last year of support is 2017.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325534&req=5

czu003-F1: Country and GAVI financing for GAVI-supported vaccines for the 14 graduating countries, 2012–18 (US$). Source: GAVI Alliance, estimates as of 26 September 2013. Note: These estimates are based on introduction dates and doses from GAVI’s adjusted demand forecast. For vaccines introduced in 2012, GAVI’s last year of support would be 2015. For introduction in 2013, GAVI’s last year of support is 2016. For introduction in 2014, GAVI’s last year of support is 2017.
Mentions: Overall, the 14 countries are expected to face varying challenges in meeting the costs of their new GAVI-supported vaccines, as external support from GAVI is phased out (see Figure 1). Total required funding for new vaccines (and injection supplies) is anticipated to grow from under US$30 million in 2012 to almost US$90 million by 2018. Funding from GAVI will peak in 2014, at US$52 million, and will then decline to zero by 2018. The financial resources required from the 14 graduating country governments will therefore need to increase from about US$8 million in 2012 to US$90 million in 2018. These projections assume that countries will obtain GAVI prices after GAVI support ends, although alternative country-specific price assumptions were used in discussions with countries. In addition, countries will need to continue to finance non-vaccine immunization costs, such as health workers, transport, demand creation and community mobilization activities, and the supply chain for vaccines.Figure 1

Bottom Line: Although all possess certain strengths, each country displayed weaknesses in some of the following areas: budgeting for vaccine purchase, national procurement practices, performance of national regulatory agencies, and technical capacity for vaccine planning and advocacy.The 2012 pilot experience further demonstrated the value of transition planning processes and tools.As a result, GAVI has decided to continue with transition planning in 2013 and beyond.

View Article: PubMed Central - PubMed

Affiliation: Consultant to Results for Development Institute, Washington, DC 20005, USA, Results for Development Institute, Washington, DC 20005, USA, World Health Organization, 1211 Geneva, Switzerland, Consultant to World Health Organization, 1211 Geneva, Switzerland, GAVI Alliance, 1202 Geneva, Switzerland rhecht@resultsfordevelopment.org.

No MeSH data available.


Related in: MedlinePlus